Israeli company Medial EarlySign has launched an AI-based product called ColonFlag to analyse electronic health records to identify patients with early-stage colorectal cancer or those at high risk of developing the disease. The colonflag software is designed for use by doctors and nurses who are not specialists in detecting early signs of cancer. The Israeli company has also launched products to identify Diabetes Type 2 patients at risk of developing chronic kidney disease. The tools will be showcased at a meeting of the American Diabetes Association in June.
Israeli company Medial EarlySign has launched an AI-based product called ColonFlag to analyse electronic health records to identify patients with early-stage colorectal cancer or those at high risk of developing the disease. The aim is to increase screening tests for at-risk individuals. The Israeli company has also launched products to identify Diabetes Type 2 patients at risk of developing chronic kidney disease. The tools will be showcased at a meeting of the American Diabetes Association in June.